ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Generation Bio raises $125 million

by Ryan Cross
March 5, 2018 | APPEARED IN VOLUME 96, ISSUE 10

Less than two months after launching with $25 million in series A funding, Generation Bio has raised $100 million in series B funding to develop its re-doseable gene therapies. Existing gene therapies require DNA to be delivered into cells via a virus, which means a therapy can’t be given to the same person twice because it will cause an immune response. Generation Bio is developing a nonviral approach that uses lipid nanoparticles to deliver a strand of close-ended DNA. The Cambridge, Mass.-based firm was founded by Atlas Venture.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment